Evidence for a Causal Role of the Renin-Angiotensin System in Vascular Dysfunction Associated with Insulin Resistance

Hypertension

Volumn 43, Issue 2 I, 2004, Pages 255-262

  Shinozaki, Kazuya ^a   Ayajiki, Kazuhide ^a   Nishio, Yoshihiko ^a   Sugaya, Takeshi ^b   Kashiwagi, Atsunori ^a   Okamura, Tomio ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Angiotensin antagonist; Angiotensin II; Blood pressure; Endothelium; Free radicals; Insulin resistance

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR 1A; ANGIOTENSIN 2 RECEPTOR 1B; ENZYME INHIBITOR; FRUCTOSE; LOSARTAN; MESSENGER RNA; OXIDOREDUCTASE; RECEPTOR SUBTYPE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STARCH; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA CONSTRICTION; ARTERY ENDOTHELIUM; ARTICLE; BIOSYNTHESIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIETARY INTAKE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME SUBUNIT; HYPERTENSION; INSULIN RESISTANCE; ISOLATED ARTERY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; TISSUE HOMOGENATE; VASCULAR DISEASE;

EID: 0842311015     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000111136.86976.26     Document Type: Article

References (44)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988; 37:1595-1607.
2. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implication for the syndrome for insulin resistance. J Clin Invest. 1996; 97:2601-2610.
3. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-357.
4. Luscher TF. Imbalance of endothelium-derived relaxing and contracting factors: a new concept in hypertension? Am J Hypertens. 1990;3: 317-330.
5. - imbalance in insulin-resistant rat aorta. Diabetes. 1999;48:2437-2445.
6. Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima H, Masada M, Toda N, Kikkawa R, Kashiwagi A. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in aortas of insulin-resistant rats. Circ Res. 2000;87: 566-573.
7. Cheetham C, Collis J, O'Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol. 2000;36: 1461-1466.
8. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
9. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck J-E, for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet. 1999;353:611-616.
10. Zuanetti G, Iatini R, Maggioni A, Franzosi M, Santoro L, Tognoni G, on behalf of the GISSI-3 Investigators. Effects of ACE-inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation. 1997;96:4239-4245.
11. Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. Lancet. 1998;351:689-690.
12. Pahor M, Psaty BM, Furberg CD. New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. J Cardiovasc Pharmacol. 1998;32:S18-S23.
13. Timmermans PBMWM, Wong PC, Chiu AT, Herbin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993; 45:205-251.
14. Navarro-Cid J, Maeso R, Perez-Vizcaino F, Cachofeiro V, Ruilope LM, Tamargo J, Lahera V. Effects of losartan on blood pressure, metabolic alterations, and vascular reactivity in the fructose-induced hypertensive rat. Hypertension 1995;26:1074-1078.
15. Leusen JHW, Meischl C, Eppink MHW, Hilarius PM, de Boer M, Weening RS, Ahlin WA, Sanders L, Goldblatt D, Skopczynska GH, Bernatowska E, Palmblad J, Verhoeven J, van Berkel H, Roos D. Four novel mutations in the gene encoding gp91-phox of human NADPH oxidase: consequences for oxidase assembly. Blood. 2000;95:666-673.
16. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, Imamura K, Goto S, Imaizumi K, Hisada Y, Otsuka A, Uchida H, Sugiura M, Fukuta K, Fukamizu A, Murakami K. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem. 1995; 270:18719-18722.
17. Harano Y, Ohgaku S, Kosugi K, Yasuda H, Nakano T, Kobayashi M, Hidaka H, Izumi K, Kashiwagi A, Shigeta Y. Clinical significance of altered insulin sensitivity in diabetes mellitus assessed by glucose, insulin, and somatostatin infusion. J Clin Endocrinol Metab. 1981;52:982-987.
18. Li Y, Zhu H, Kuppusamy P, Roubaud V, Zweier JL, Trush MA. Validation of lucigenin (Bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems. J Biol Chem. 1998;273:2105-2023.
19. Mohazzab-H K, Wolin MS. Sites of superoxide anion production detected by lucigenin in calf pulmonary artery smooth muscle. Am J Physiol. 1994;267:L815-L822.
20. Bunag RD. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol. 1973;34:279-282.
21. Toda N, Ayajiki K, Okamura T. Endothelial modulation of concentrations caused by oxyhemoglobin and NG-nitro-L-arginine in isolated dog and monkey cerebral arteries. Stroke. 1993;24:1584-1589.
22. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
23. Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989;86:9717-9721.
24. Ugi S, Maegawa H, Kashiwagi A, Adachi M, Olefsky JM, Kikkawa R. Expression of dominant negative mutant SHPTP2 attenuates phosphatidylinositol 3′-kinase activity via modulation of phosphorylation of insulin receptor substrate-1. J Biol Chem. 1996;271:12595-125602.
25. Weber C, Erl W, Pietsch A, Ströbel M, Ziegler-Heitbrock HWL, Weber PC. Antioxidant inhibit monocyte adhesion by suppressing nuclear factor-κB mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. Arterioscler Thromb. 1994;14:1665-1673.
26. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1996;97:22-28.
27. Kontos HA, Kontos MC. Role of products of univalent reduction of oxygen in hypertensive vascular injury. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York: Raven Press; 1995:685-696.
28. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
29. Mohazzab-H KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary endothelium. Am J Physiol. 1994;266:H2568-H2572.
30. Thomas T, Thomas G, McLendon C, Sutton Tmullan M. b-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 1996; 380:168-171.
31. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vascular tone. J Clin Invest. 1996;97:1916-1923.
32. Kamide K, Rakugi H, Higaki J, Okamura A, Nagai M, Moriguchi K, Ohishi M, Satoh N, Tuck ML, Ogihara T. The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. Am J Hypertens. 2002;15:66-71.
33. Pueyo ME, N'Diaye N, Michel J-B. Angiotensin I. I-elicited signal transduction via AT1 receptors in endothelial cells. Br J Pharmacol. 1996;118:79-84.
34. van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In 't Veld AJ. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension. 1995;25: 22-29.
35. Sohn HY, Raff U, Hoffmann A, Gloe T, Heermeier K, Galle J, Pohl U. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br J Pharmacol. 2000;131:667-672.
36. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OTG. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol. 1996;271:H1626-H1634.
37. Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, Ballinger CA, Brasier AR, Bode C, Runge MS. Stimulation of a vascular smooth cell NAD(P)H oxidase by thrombin: evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem. 1999;274:19814-19822.
38. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R. A gp91phox containing NADPH oxidase in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res. 2000; 87:26-32.
39. Guzik TJ, Mussa S, Gastaldi D, Sadwoski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus. Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002;105:1656-1662.
40. Katoh M, Egashira K, Usui M, Ichiki T, Tomita H, Shimokawa H, Rakugi H, Takeshita A. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res. 1998;83: 743-751.
41. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation. 1997;95:473-478.
42. Murphy TJ, Alexander AW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin receptor. Nature. 1991;351:233-236.
43. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension. 2001;38:884-890.
44. Kudoh A, Matsuki A. Effects of angiotensin-converting enzyme inhibitors on glucose uptake. Hypertension. 2000;36:239-244.